vimarsana.com

Latest Breaking News On - Thomas feldthus - Page 1 : vimarsana.com

SANA : Minutes from the AGM 2024 (unofficial translation)

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. .

New yorkUnited statesUnited kingdomAnnika bostrSetterwalls advokatbyrThomas feldthusInrikes tidningarDan petersOla grahnAnna ljungPierandrea mugliaCarl johan sundbergCecilia andrSvenska dagbladetJohn haurumInstitute of molecular medicine

SANA : Interim Report Q1 2024 - MarketScreener

INTERIM REPORT FOR SANIONA AB 556962-5345 January - March 2024 Published May 29, 2024 Advancing our epilepsy assets and driving innovation.

Boehringer ingelheim gmbFormue nordThomas feldthusProductos medixBoehringer ingelheimBoehringer ingelheim gmbhAstronautx limitedNasdaq stockholm mainPositive allosteric modulatorGenetic absence epilepsy ratTrigeminal neuralgiaPositron emission tomography

Investegate |Saniona AB Announcements | Saniona AB: Saniona AB s Nomination Committee for the Annual General Meeting 2023

Investegate announcements from Saniona AB, Saniona AB’s Nomination Committee for the Annual General Meeting 2023

United kingdomBoehringer ingelheim gmbDan petersThomas feldthusProductos medixJohn haurumNomination committee for theSaniona ab nomination committee for theNomination committeeNomination committee in sanionaSaniona ab nomination committeeAnnual general meetingF star biotechnology limitedAnnual generalCorporate governanceGeneral meeting

Saniona AB s Nomination Committee for the Annual General Meeting 2023

PRESS RELEASE November 25, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced the composition of the Nomination Committee for the Annual General Meeting

United kingdomBoehringer ingelheim gmbDan petersThomas feldthusProductos medixJohn haurumNomination committee for theNomination committeeNomination committee in sanionaSaniona ab nomination committeeAnnual general meetingF star biotechnology limitedAnnual generalCorporate governanceGeneral meetingThursday may

Saniona AB: Saniona publishes its interim report for the third quarter of 2022

Three Months Ended September 30, 2022 (2021)Nine Months Ended September 30, 2022 (2021)Revenue was SEK 2.4 M (2.3 M)Revenue was SEK 12.0 M (7.6 M)Operating profit/loss was SEK 21.8 M (-88.2 M)Net profit/loss

United kingdomBoehringer ingelheim gmbFormue nordThomas feldthusProductos medixThree months ended septemberMonths ended septemberAbuse regulationandSecurities marketsBoehringer ingelheim gmbhNasdaq stockholm small

vimarsana © 2020. All Rights Reserved.